Blog
Daily evidence-led peptide research, regulatory news, expert digest and explainers. Every claim sourced; no AI tells.
Page 79
Semaglutide vs SGLT2 inhibitors in MASLD
A propensity-matched TriNetX study compares semaglutide against SGLT2 inhibitors in patients with fatty liver disease and type-2 diabetes.
Tirzepatide vs GLP-1s in spinal fusion
A 2026 retrospective study found tirzepatide users had fewer complications and revisions after spinal fusion than single-receptor GLP-1 agonist users.
Weight-loss drugs and fertility: the data
A meta-analysis of seven trials finds orlistat and semaglutide may boost ovulation and pregnancy rates in women with obesity.
BPC-157 side effects: what the data shows
BPC-157 has no approved label and no completed human safety trial. Here is what preclinical toxicology actually shows.
BPC-157 and anxiety: what the evidence says
Rodent studies suggest BPC-157 has anxiolytic effects. Human self-reports are mixed. No controlled human trial has measured anxiety as an outcome.
BPC-157 oral vs injectable for gut health
No human trial has compared oral BPC-157 tablets to reconstituted injectable for gut health. Here is what rodent data and the supply chain show.
BPC-157 personal reviews: what they show
Personal peptide reviews name doses and outcomes but lack controls and verified purity. Here is how to read them against actual BPC-157 data.
Is BPC-157 prohibited in sport? WADA rules
BPC-157 is banned under S0 of the WADA Prohibited List. Here is how the rule works, what USADA enforces, and what athletes need to know.
How BPC-157 works: a plain-English guide
BPC-157 appears to promote tissue repair in rodents through angiogenesis and nitric-oxide signalling. Here is what the preclinical data shows.
BPC-157 dosing: what the studies used
No validated human dose for BPC-157 exists. The 200 to 500 mcg range quoted online is an allometric extrapolation from rodent injury models, not clinical data.
Is BPC-157 legal? Status by country
BPC-157 is not approved for human use in any country we cover. Here is the regulatory status across the US, EU, and UK as of mid-2026.
What is BPC-157? A plain-English explainer
BPC-157 is a synthetic peptide from human gastric juice studied in rodents for tissue repair. No controlled human trial exists, and it is not approved anywhere.